The ELANE knockout KYSE-30 polyclonal cells are a genetically disrupted cell population generated using CRISPR/Cas9-mediated gene editing to target the ELANE locus in the KYSE-30 human esophageal squamous cell carcinoma line. This product comprises a heterogeneous pool of edited cells, representing a polyclonal knockout model that circumvents clonal selection artifacts and preserves population diversity. The resulting loss-of-function system enables robust investigation of neutrophil elastase biology in a cancer-relevant context. As a polyclonal population, these cells retain the genetic background variability inherent in the parental line, making them suitable for studies requiring representation of mixed genotypes while eliminating ELANE protein expression.
The host cell line, KYSE-30, is a well-differentiated esophageal squamous cell carcinoma originally isolated from a Japanese male patient. This epithelial-derived line is extensively used as a model for esophageal cancer pathology, including tumor growth, differentiation, and therapeutic resistance mechanisms. KYSE-30 cells harbor molecular features characteristic of squamous cell carcinomas, providing a physiologically relevant surrogate for investigating disease mechanisms. Their adherent growth and robust manipulation compatibility facilitate a broad range of cell-based assays, establishing this line as a standard tool in translational esophageal cancer research.
ELANE encodes neutrophil elastase, a serine protease that degrades extracellular matrix components such as elastin and collagen, and processes pro-inflammatory cytokines including IL-1?? and TNF-??. The enzyme is transcriptionally regulated by the myeloid transcription factors C/EBP?? and PU.1, and is activated downstream of GM-CSF signaling and formyl peptide receptor (fMLP) stimulation. ELANE activity is counterbalanced by endogenous inhibitors like SERPINA1 (??1-antitrypsin), SLPI, and elafin. In the context of the neutrophil degranulation pathway, ELANE functions alongside Cathepsin G, Proteinase 3, and Myeloperoxidase to mediate extracellular proteolysis and facilitate formation of neutrophil extracellular traps (NETs). Proteolytic activation of proteinase-activated receptors (PARs) further disseminates elastase-dependent signals, linking matrix remodeling to cellular responses.
In KYSE-30 esophageal cancer cells, ELANE knockout disrupts the proteolytic capacity that may contribute to tumor microenvironment remodeling. While neutrophil elastase is primarily myeloid-derived, its ectopic expression or paracrine uptake in cancer cells can promote invasion and inflammatory signaling. By eliminating ELANE activity, this model permits dissection of tumor-intrinsic roles of elastase-mediated proteolysis, independent of immune cell contributions. This system is particularly relevant for exploring how cancer cells may co-opt neutrophil-derived proteases to degrade extracellular barriers, modulate cytokine bioavailability, and engage PAR signaling, thereby affecting migration, survival, and immune evasion in the esophageal cancer milieu.
This knockout cell product is designed for diverse research applications, including functional studies of ELANE in esophageal carcinogenesis, validation of neutrophil elastase as a therapeutic target, and screening of elastase inhibitors. Standard downstream assays include Western blotting and RT-qPCR to confirm ELANE ablation, elastase activity assays to verify functional loss, and gelatin zymography to monitor proteolytic capacity. Migration and invasion assays using scratch wound or transwell formats, as well as immunofluorescence for elastase, are facilitated by this system. Co-culture experiments with immune cells enable investigation of tumor?Cstroma crosstalk mediated by neutrophil-derived factors. For additional technical details or to discuss experimental customization, please contact Ascent Research.
